| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5585089 | WYETH PHARMS INC | Humanized immunoglobulins |
Dec, 2013
(10 years ago) | |
| US5606040 | WYETH PHARMS INC | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
Feb, 2014
(10 years ago) | |
| US5693762 | WYETH PHARMS INC | Humanized immunoglobulins |
Dec, 2014
(9 years ago) | |
| US5739116 | WYETH PHARMS INC | Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents |
Apr, 2015
(9 years ago) | |
| US5767285 | WYETH PHARMS INC | Linkers useful for the synthesis of conjugates of methyltrithio antitumor agents |
Jun, 2015
(8 years ago) | |
| US5773001 | WYETH PHARMS INC | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
Jun, 2015
(8 years ago) | |
Mylotarg is owned by Wyeth Pharms Inc.
Mylotarg contains Gemtuzumab Ozogamicin.
Mylotarg has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Mylotarg are:
- US5585089
- US5606040
- US5693762
- US5739116
- US5767285
- US5773001
Mylotarg was authorised for market use on 17 May, 2000.
Mylotarg is available in injectable;injection dosage forms.
Mylotarg can be used as inhibiting or eliminating acute myeloid leukemia.
The generics of Mylotarg are possible to be released after 30 June, 2015.
Drugs and Companies using GEMTUZUMAB OZOGAMICIN ingredient
Market Authorisation Date: 17 May, 2000
Treatment: Inhibiting or eliminating acute myeloid leukemia
Dosage: INJECTABLE;INJECTION
More Information on Dosage
MYLOTARG family patents
